PregLem SA

15 articles about PregLem SA

• Watson Pharmaceuticals, Inc. and Gedeon Richter Announce Exclusive License Agreement with PregLem SA for Esmya(TM); Watson to pay PregLem $17M

  12/16/2010

• Ipsen Sells its Shares in PregLem SA to Gedeon Richter Ltd.

  10/11/2010

• Richter International, Inc. Buys Swiss PregLem SA for up to $461 Million

  10/8/2010

• PregLem SA Announces In-Licensing Deal With Merck Serono For Post-Operative Adhesions & Endometriosis

  8/11/2010

• PregLem SA Said to Hire Credit Suisse for Possible Initial Public Offering

  7/9/2010

• PregLem SA Announces Positive Phase III Results for Esmya(TM)

  6/3/2010

• PregLem SA Announces Positive Phase 3 Results For Esmya(TM) as an Effective Treatment For Uterine Fibroids; PEARL II Study Meets Both Primary Efficacy and Safety Endpoints

  5/19/2010

• PregLem SA Presenting At JP Morgan Healthcare Conference

  1/12/2010

• PregLem SA Announces The Appointment Of Dr Suhail Nurbhai As Chief Medical Officer

  6/2/2009

• Fritz Kunz Joins PregLem SA's Board of Directors

  9/4/2008

• PregLem SA Starts Phase III Trials of PGL4001 in Uterine Myoma

  8/19/2008

• PregLem SA Starts Phase III Trials of PGL4001 in Uterine Myoma

  8/19/2008

• PregLem SA Initiates SAPHIR Study for Endometriosis

  3/12/2008

• PregLem SA Announces CHF 32 Million Series A Funding

  6/27/2007

• Ipsen Announces License Agreement With PregLem SA In Field of Reproductive Medicine

  6/27/2007